Opioids Library
ISO 17025–ACCREDITED LABORATORY ENVIRONMENT
Opioids DMPK and Bioanalytical Services
Opioid bioanalysis is defined by metabolic diversity unmatched by any other class in this library. Codeine is a CYP2D6 prodrug — its active metabolite, morphine, is a separate compound in this same drug index. Morphine itself is metabolized not by CYP but by UGT2B7 Phase II glucuronidation. Tramadol straddles both prodrug activation and Phase I metabolism. Buprenorphine spans CYP3A4 Phase I and UGT Phase II simultaneously. The remaining five opioids follow CYP3A4/CYP2D6 Phase I metabolism. No single cofactor, no single enzyme panel, and no single incubation protocol serves all nine compounds — because the metabolite of one opioid is the parent drug of another.
Creative Proteomics provides CYP2D6 prodrug activation monitoring, CYP Phase I metabolic profiling, UGT Phase II glucuronidation analysis, dual-cofactor Phase I+II profiling, and custom multi-opioid panels with mechanism-matched incubation arms.
Prodrug Activation: Codeine & TramadolCodeine (CYP2D6→morphine) and tramadol (CYP2D6→active metabolite) require prodrug activation monitoring with NADPH cofactor.
Phase II GlucuronidationMorphine (UGT2B7) and buprenorphine (UGT) require UDPGA cofactor. Morphine needs no NADPH at all.
Metabolite = Next CompoundCodeine CYP2D6 metabolism produces morphine — a separate entry in this index. Sequential pathway, dual-compound readout.
Opioid Metabolic Diversity DMPK Strategy Map
⚡
Prodrug Activation (NADPH)Codeine (CYP2D6→morphine), tramadol (CYP2D6→active metabolite). Prodrug activation monitoring — simultaneous parent-prodrug and active metabolite quantification.
🧬
CYP Phase I Metabolism (NADPH)Fentanyl (CYP3A4), pethidine (CYP3A4/2B6), oxycodone/hydrocodone (CYP3A4/2D6), methadone (CYP3A4/2B6/2C19) — multi-isoform incubation.
📊
Phase II Glucuronidation (UDPGA)Morphine (UGT2B7, UDPGA-only, no NADPH). Buprenorphine (UGT+CYP3A4, both cofactors). Two distinct Phase II strategies.
🔬
Sequential Pathway AnalyticsCodeine→morphine via CYP2D6, morphine→glucuronide via UGT2B7. One compound's metabolite is another's parent — two linked assays in sequence.
Opioid mechanism mapping before method development.Creative Proteomics classifies each opioid as CYP prodrug, CYP Phase I substrate, UGT Phase II substrate, or dual Phase I+II — because codeine's metabolite IS morphine, and a NADPH-only incubation misses both the prodrug activation step and the downstream UGT2B7 glucuronidation.
